Full-scale entry into the primary care sector
First written in FY2018. 3 of 6 entries say "Restated". Latest entry: FY2024.
0 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「We launched in Europe a rapid antimicrobial susceptibility testing system that uses urine samples from patients suspected of having urinary tract infections to determine the presence of bacteria and the effectiveness of antibiotics in as little as approximately 30 minutes after measurement begins.」
The European launch of a rapid antimicrobial susceptibility testing system for urinary tract infections in the primary care field has been reiterated. - FY2024-Q1AdvancedAnnual report
「June 2023: We launched in Europe a rapid antimicrobial susceptibility testing system that uses urine samples from patients suspected of having urinary tract infections to determine the presence of bacteria and the effectiveness of antibiotics in as little as approximately 30 minutes after measurement begins.」
In primary care, the Company launched a rapid antimicrobial susceptibility testing system for urinary tract infections in Europe, taking concrete steps toward providing results in as little as approximately 30 minutes and contributing to measures against antimicrobial resistance. - FY2023RestatedAnnual report
「Our Group is working to expand its existing in vitro diagnostics business, promote personalized medicine tailored to each individual’s characteristics, and advance primary care, which provides testing closer to patients.」
Personalized medicine and primary care, which provides testing closer to patients, have been reiterated as ongoing R&D themes. - FY2021AdvancedAnnual report
「Our Group is working to expand its existing in vitro diagnostics business, promote personalized medicine tailored to each individual’s characteristics, and advance primary care, which provides testing closer to patients.」
The policy of advancing primary care continued, and concrete steps were taken toward developing new urine testing solutions through an investment in Astrego Diagnostics AB. - FY2020RestatedAnnual report
「Our Group is working to expand its existing in vitro diagnostics business, promote personalized medicine tailored to each individual’s characteristics, and advance primary care, which provides testing closer to patients.」
In addition to personalized medicine, primary care, which provides testing closer to patients, has been reiterated as an ongoing R&D theme. - FY2018First statedAnnual report
「We will pursue full-scale entry into primary care, a field in which the market is expected to expand.」
The Company identified primary care, which provides patients with accessible initial medical care, as a new area of entry and stated for the first time, as an independent theme, its policy of creating services by leveraging diagnostic technologies accumulated through specimen testing and IT.